UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2024

 

OR

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________________ to __________________

 

Commission File No. 000-56253

 

CHARGING ROBOTICS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   26-2274999
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

20 Raul Wallenberg Street

Tel AvivIsrael, 6971916

(Address of principal executive offices, zip code)

 

(+972) 54 642-0352

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):

 

Large accelerated filer Accelerated filer
Non-accelerated Filer Smaller reporting company
    Emerging Growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act):  Yes ☐ No  

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

As of September 30, 2024, and November 13, 2024, there were 9,152,228 shares of common stock, par value $0.0001 per share, issued and outstanding.

 

 

 

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

 

TABLE OF CONTENTS

 

  Page
Part I. Financial Information 1
   
  Item 1. Consolidated Financial Statements (Unaudited) 1
       
    Condensed Consolidated Balance Sheets as at September 30, 2024 (Unaudited) and December 31, 2023 (Audited) 1
       
    Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and September 30, 2023 (Unaudited) 2
       
    Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and September 30, 2023 (Unaudited) 3
       
    Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and September 30, 2023 (Unaudited) 4
       
    Notes to the Condensed Consolidated Financial Statements (Unaudited) 5
       
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
       
  Item 3. Quantitative and Qualitative Disclosures About Market Risk 18
       
  Item 4. Controls and Procedures 18
       
Part II. Other Information 19
   
  Item 1. Legal Proceedings 19
       
  Item 1A. Risk Factors 19
       
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19
       
  Item 3. Defaults Upon Senior Securities 19
       
  Item 4. Mine Safety Disclosures 19
       
  Item 5. Other Information 19
       
  Item 6. Exhibits 19
       
Signatures 20

 

i

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q of Charging Robotics Inc. (formerly Fuel Doctor Holdings, Inc.), a Delaware corporation (the “Company”), contains “forward-looking statements.” In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: the Company’s need for and ability to obtain additional financing and the demand for the Company’s products, and other factors over which we have little or no control; and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”).

 

We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as required by law.

 

ii

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1: CONSOLIDATED FINANCIAL STATEMENTS.

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands except share and per share data

 

  

September 30,

2024

   December 31,
2023
 
   (Unaudited)   (Audited) 
ASSETS        
Current assets:        
Cash  $6   $8 
Other accounts receivable   19    43 
Total current assets   25    51 
           
Non current assets:          
Intangible asset   104    100 
Investment in an affiliate (Note 4)   78    110 
Loan to an affiliate (Note 4)   64    62 
Total non current assets   246    272 
           
TOTAL ASSETS  $271   $323 
           
LIABILITIES & STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $92   $104 
Other current liabilities   197    116 
Receipt on account of shares   85    
-
 
Short term loans   340    30 
Related parties (Note 5)   160    98 
Total current liabilities   874    348 
           
Non-current liabilities:          
Deferred revenues  $31   $49 
           
Total liabilities  $905   $397 
           
Stockholders’ deficit (Note 6)          
Preferred shares of the Company, par value $0.0001 per share, 10,000,000 shares authorized, 0 shares issued and outstanding on each of September 30, 2024 and December 31, 2023   
-
    
-
 
Common Stock, par value $0.0001, 2,990,000,000 shares authorized, 9,152,228 shares issued and outstanding on each of September 30, 2024 and December 31, 2023   1    1 
Additional paid-in capital   1,817    1,817 
Foreign currency transaction reserve   (29)   (27)
Reserve from share-based compensation transactions   123    101 
Accumulated deficit   (2,546)   (1,966)
           
Total stockholders’ deficit   (634)   (74)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $271   $323 

 

See accompanying Notes to Condensed Consolidated Financial Statements 

 

1

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

U.S. dollars in thousands except share and per share data
(Unaudited)

 

   Three months ended   Nine months ended 
   September 30,
2024
   September 30,
2023
   September 30,
2024
   September 30,
2023
 
                 
Research and development costs  $78   $145   $226   $294 
General and administrative costs   107    127    320    210 
Operating loss   (185)   (272)   (546)   (504)
Financial expenses   (7)   
-
    (4)   
-
 
Net loss   (192)   (272)   (550)   (504)
Share in losses of affiliate   (7)   (14)   (30)   (24)
Net loss for the period   (199)   (286)   (580)   (528)
Other comprehensive loss   1    (20)   (2)   (20)
Net loss and comprehensive loss for the period   (198)   (306)   (582)   (548)
                     
Basic and diluted loss per common share   (0.02)   (0.03)   (0.06)   (0.09)
Weighted average common shares outstanding (*)   9,152,228    9,152,228    9,152,228    5,796,304 

 

(*) On April 23, 2024, the Company received notice from FINRA that the Reverse Stock Split has been announced on FINRA’s daily list and will take effect at market open on April 24, 2024 (the “Market Effective Date”). Accordingly, the FINRA corporate action to effect the Reverse Stock Split is now completed. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.

 

See accompanying Notes to Condensed Consolidated Financial Statements

 

2

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

U.S. dollars in thousands except share and per share data

For the nine months ended September 30, 2024

(Unaudited)

 

   Common Stock   Additional Paid in   Stock-based   Accumulated
other
comprehensive
   Accumulated   Total Shareholders’ 
   Number   Amount   capital   compensation   loss   Deficit   Deficit 
                             
Balance at January 1, 2024   9,152,228   $    1   $1,817   $101   $   (27)  $(1,966)  $(74)
Issuance of warrant                  18              18 
Share-based payment reserve   -    
-
    
-
    4    
-
    
-
    4 
Net comprehensive loss for the period   -    
-
    
-
    
-
    (2)   (580)   (582)
Balance at September 30, 2024   9,152,228   $1   $1,817   $123   $(29)   (2,546)  $(634)

 

   Common Stock   Additional Paid in   Stock-based   Accumulated
other
comprehensive
   Accumulated   Total Shareholders’ 
   Number   Amount   capital   compensation   loss   Deficit   Equity 
                             
Balance at January 1, 2023   182   $
    -
   $741   $91   $   (12)  $(1,188)  $(368)
Exercise of options   27    
-
    91    9    
-
    
-
    100 
Issuance of shares in respect of converted loan   51    
-
    509    
-
    
-
    
-
    509 
Effect of reverse merger   8,241,968    1    (25)   
-
    
-
    
-
    (24)
Issuance of shares in respect of private placement   910,000    
-
    501    
-
    
-
    
-
    501 
Net comprehensive loss for the period   -    
-
    
-
    
-
    (20)   (528)   (548)
Balance at September 30, 2023   9,152,228   $1   $1,817   $100   $(32)  $(1,716)  $170 

 

(*) On April 23, 2024, the Company received notice from FINRA that the Reverse Stock Split has been announced on FINRA’s daily list and will take effect at market open on April 24, 2024 (the “Market Effective Date”). Accordingly, the FINRA corporate action to effect the Reverse Stock Split is now completed. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.

 

See accompanying Notes to Condensed Consolidated Financial Statements

 

3

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 U.S. dollars in thousands except share and per share data
(Unaudited)

 

   For the nine months ended 
   September 30, 
   2024   2023 
CASH FLOWS FROM OPERATING ACTIVITIES:        
         
Net loss  $(580)  $(528)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share-based payment expenses   4    9 
Share in losses of affiliate   30    24 
Interest expenses   16    
-
 
Changes in operating assets and liabilities:          
Decrease (increase) in other accounts receivable   24    25 
Increase (decrease) in related parties   62    26 
Increase (decrease) in accounts payable   (12)   (99)
Increase in other accounts payable and accrued expenses   81    32 
Net cash used in operating activities   (375)   (511)
           
CASH FLOWS USED IN INVESTING ACTIVITIES:          
Effect of reverse merger   (4)   3 
Net cash used in investing activities   (4)   3 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from issuance of shares in respect of a private placement   
-
    500 
Proceeds from short term loans received   292    
-
 
Proceeds on account of shares   85    
-
 
Proceeds from exercise of options   
-
    91 
Net cash provided by financing activities   377    591 
           
Net increase (decrease) in cash   (2)   83 
Effect of changes in foreign exchange rates   
-
    1 
Cash at beginning of period   8    27 
           
Cash at end of period  $6   $111 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the period for:          
Interest  $
-
   $
-
 
Franchise taxes  $
-
   $
-
 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:          
Issuance of shares to in respect of converted loan  $
-
   $509 
Issuance of warrants in respect of deferred revenue  $18   $
-
 

 

See accompanying Notes to Condensed Consolidated Financial Statements

 

4

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 1 – GENERAL

 

Charging Robotics Inc. (formerly Fuel Doctor Holdings, Inc.) (the “Company”) was incorporated in the State of Delaware on March 25, 2008, as Silver Hill Management Services, Inc. On August 24, 2011, the Company amended its Certificate of Incorporation and changed its name to Fuel Doctor Holdings, Inc, and on April 23, 2024, the Company changed its name to Charging Robotics Inc.

 

On March 28, 2023, the Company entered into a Securities Exchange Agreement (the “Acquisition Agreement”) with the stockholders of Charging Robotics Ltd. (“CR Israel”). Pursuant to the Acquisition Agreement, at the closing, which occurred on April 7, 2023 (the “Closing”), the Company acquired 100% of the issued and outstanding stock of CR Israel (the “Acquisition”), making CR Israel a wholly owned subsidiary of the Company.

 

CR Israel was formed in February 2021, as an Israeli corporation, with the main goal of developing an innovative wireless electric vehicles (EV) charging technology. At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer electricity wirelessly. This module can be used for various products such as robotic and stationary platforms. The robotic platform includes a component which is small enough to fit under the vehicle, and which automatically positions itself for maximum-efficiency charging, and upon charging completion automatically returns to its docking station. CR Israel also developed a Wireless EV Charging System for automatic parking lots based on our wireless electricity transfer module.

 

On April 6, 2023, the Company issued a total of 910,000 newly issued shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) in respect of a private placement for total proceeds of $500.

 

On November 22, 2023, the Company announced that CR Israel received approval for funding from the Israel Innovation Authority (the “IIA”) for a pilot project to include installing and demonstrating its solution for wireless charging of electric vehicles (EVs) in automated parking systems (“APS”). The total approved budget for this project was approximately $445, of which the IIA would finance 50%. The Company is now engaged in the pilot project to implement the solution in an APS in Tel Aviv. In December 2023, CR Israel received $77 from the IIA, and on February 14, 2024, CR Israel received an additional $33 from the IIA.

 

On August 28, 2023, the Company filed an amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”), to (i) change its name to Charging Robotics Inc. (the “Name Change”); and (ii) effect a one-for-one hundred fifty reverse stock split (the “Reverse Stock Split”) of its outstanding shares of Common Stock.

 

On August 28, 2023, the Company submitted an Issuer Company-Related Action Notification Form to the Financial Industry Regulatory Authority, Inc. (“FINRA”) regarding the Name Change and Reverse Stock Split.

 

On April 23, 2024, the Company received notice from FINRA that the Name Change and the Reverse Stock Split was announced on FINRA’s daily list and would take effect at market open on the Market Effective Date. Accordingly, the FINRA corporate action to effect the Name Change and the Reverse Stock Split was completed on April 23, 2024.

 

5

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 1 – GENERAL (CONT.)

 

Basis of presentation of the financial statements:

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments consisting of a normal recurring nature which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented.

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report for the year ended December 31, 2023, filed with the SEC on March 12, 2024. The interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

 

NOTE 2 – UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

 

The financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP).

 

  a. Use of estimates:

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to share-based compensation and the Company’s ability to continue as a going concern.

 

  b. Financial statements in U.S. dollars:

 

The costs of the Company are denominated in United States dollars (“dollars”). Some of the costs in our Israeli associate are incurred in New Israeli Shekels (NIS), however the selling prices will be linked to the Company’s price list which will be determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and its subsidiary operates. Thus, the dollar is the Company’s and its subsidiary functional and reporting currency.

 

Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the statements of operations as appropriate.

 

The functional currency of the affiliate company is the NIS and therefore foreign exchange differences are charged to the other comprehensive profit and loss.

 

  c. Cash and cash equivalents:

 

Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.

 

  d. Investment in affiliated companies

 

Affiliated company is company held to the extent of 20% or more (which are not subsidiary), or company less than 20% held, which the Company can exercise significant influence over operating and financial policy of the affiliate.

 

6

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 2 – UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS (CONT.)

 

The investment in the affiliated company is accounted for by the equity method under ASC Subtopic 323-30, “Investments - Equity Method and Joint Ventures: Partnerships, Joint Ventures, and Limited Liability Entities”. Upon initial recognition, the cost of investment is based on the direct costs of acquiring the investment including amounts incurred on behalf of the investee.

 

Following the acquisition, the Company recognizes its proportionate share of the affiliated company’s net income or loss after the date of investment. When previous losses have reduced the Common Stock investment account to zero, the Company continues to report its share of equity method losses in its statement of operations to the extent of and as an adjustment to other investments in the investee such as debt securities, long term loans or advances, if any. Such additional equity method losses are applied to the other investments based on the seniority of the other investments (priority in liquidation) and the percentage ownership interest in each type of other investment the Company holds (the ‘relative holdings approach’).

 

  e. Impairment of long-lived assets:

 

The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the year ended December 31, 2023, no impairment losses were recorded.

 

  f. Concentration of credit risks:

 

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings.

 

The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.

 

  g. Research and development expenses:

 

Research and development costs are charged to the statement of operations as incurred.

 

  h. Fair value of financial instruments:

 

ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

7

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 2 – UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS (CONT.)

 

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  Level 1 Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.
       
  Level 2 Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
       
  Level 3 Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying amounts of cash and cash equivalents, other current assets, accounts payables and current liabilities approximate their fair value due to the short-term maturity of such instruments.

 

  i. Income Tax:

 

The Company account for income taxes in accordance with ASC 740, “Income Taxes” which prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will be realized. Based on ASC 740, a two-step approach is used to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.

 

The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2023, no liability for unrecognized tax positions has been recorded. Accordingly, no interest or penalties related to uncertain tax positions are recorded, either. It is the Company’s policy that any interest or penalties associated with unrecognized tax positions would be reflected in income tax expense.

 

  j. Contingencies:

 

The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

8

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 2 – UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS (CONT.)

 

  k. Stock-based payments:

 

The Company measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.

 

Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, “Equity-Based Payments to Non-Employees”.

 

For the nine months ended September 30, 2024, the Company recorded $4, in share-based compensation (see note 5(b)).

 

Basis of Presentation and Principles of Consolidation:

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”)

 

All intercompany accounts and transactions have been eliminated in consolidation.

 

Unaudited Interim Financial Information

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

 

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the nine months ended September 30, 2024, are not necessarily indicative of the results for the year ending December 31, 2024, or for any future period.

 

Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 12, 2024 (the “2023 Annual Report”).

 

As of September 30, 2024, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2023 Annual Report.

 

9

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 3 – GOING CONCERN

 

The condensed consolidated financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred a loss since inception resulting in an accumulated deficit of $1,966, as of December 31, 2023, and $2,546, as of September 30, 2024, and further losses are anticipated in the development of its business. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources and through additional raises of capital.

 

Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors. However, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

 

NOTE 4 – INVESTMENT IN AFFILIATED COMPANY

 

  a. On April 24, 2021, CR Israel invested $250 and purchased 19.99% of the share capital of Revoltz Ltd (“Revoltz”), an Israeli private company focusing on research, development and production of micro-mobility vehicles for the urban environment for the business and the private markets.

 

  b. On July 28, 2022, CR Israel entered into a convertible loan agreement with Revoltz pursuant to which CR Israel was required to invest an amount of $60 in Revoltz (the “Loan Principal Amount”). In addition, CR Israel provided Revoltz further lending of up to $340 (the “Additional Amount”, and together with the Loan Principal, the “Total Loan Amount”). The Total Loan Amount shall carry interest at the minimum rate prescribed by Israeli law.

 

The Total Loan Amount shall be converted into shares of Revoltz, upon the occurrence of any of the following events (each a “Trigger Event”):

 

  i) The consummation of funding by Revoltz of an aggregate amount of $1,000 at a pre-money Revoltz valuation of at least $7,000 (in the form of SAFE, equity or otherwise);

 

  ii) Revoltz has generated an aggregate of $1,000 or more in revenue.

 

In the event that a Trigger Event shall not have occurred on or prior to the 24-month anniversary of the date on which the Loan Principal Amount is actually extended to Revoltz, the Loan shall be due and repayable by Revoltz to the Company.  

 

On September 30, 2024, the balance of the Loan Principal Amount was $64.  

 

  c. The following table summarizes the equity method accounting for the investment in affiliated company:

 

Balance January 1, 2023  $152 
Share in losses of affiliated company   (27)
Foreign currency translation   (15)
Balance December 31, 2023  $110 
Share in losses of affiliated company   (30)
Foreign currency translation   (2)
Balance September 30, 2024  $78 

 

10

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE condensed CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 5 – RELATED PARTIES

 

  a. In support of the Company’s efforts and cash requirements, the Company may rely on advances from related parties until such a time that the Company can support its operations or attains adequate financing through sales of stock or traditional debt financing. There is no formal written commitment for continued support by related parties.

 

  (i) The compensation to key management personnel for employment services they provide to the Company is as follows:  

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2024   2023   2024   2023 
Consulting Fees – CEO  $20   $21   $60   $63 
Consulting Fees - CFO  $9   $12   $27   $32 
Directors’ compensation  $21   $21   $63   $42 

 

  (ii) Balances owed to (by) related parties

 

   September 30,   December 31, 
   2024   2023 
Consulting Fees – CEO  $20   $8 
Consulting Fees – CFO   12    8 
Directors   70    27 
Revoltz (see note 4b)   (64)   (62)
Xylo (see note 5c)   57    55 
   $95   $36 

 

  b. The Company currently operates out of an office of a related party free of rent.

 

  c. As of January 1, 2023, CR Israel owed Xylo Technologies Ltd., f/k/a Medigus Ltd., a related party (“Xylo”) $550 (the “Xylo Loan”). The Xylo Loan bears interest in accordance with section 3(i) of the Israeli tax code (2.42% annually during 2022) and no fixed date for repayment has been determined. On January 1, 2023, CR Israel and Xylo signed an agreement to amend the terms of the Xylo Loan (the “Xylo Loan Agreement”). Pursuant to the Xylo Loan Agreement, the interest rate remains unchanged, and the capital and interest was to be repaid in cash or shares, or a combination thereof by June 30, 2023. On April 4, 2023, the Xylo Loan balance owing was $553. $509 of the Xylo Loan was converted into 28 shares of CR Israel and the remaining Xylo Loan balance will be repaid in cash. The Company is in discussions with Xylo to extend the repayment date of the remaining loan balance.

 

  d. On October 1, 2021, CR Israel signed a consulting agreement with the CEO, pursuant to which CR Israel will pay the CEO a monthly fee of NIS 24,700 (approximately $7). Subject to approval of CR Israels’ board of directors (“Board”), the CEO shall be entitled to receive stock options in the Company that will entitle him to own 3% of Charging Robotics. The options will have an exercise price equivalent to a Company valuation of $10,000. As of the date of this report, the options have not been issued as the Board has not yet approved their issuance.

 

During the nine months ended September 30, 2024, the CEO earned $60 (during the nine months ended September 30, 2023 - $63).

 

11

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE condensed CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 6 – COMMON STOCK AND PREFERRED STOCK

 

  a. As of September 30, 2024, and December 31, 2023, the Company’s share capital is composed as follows:

 

   September 30, 2024   December 31, 2023 
   Authorized   Issued and
outstanding
   Authorized   Issued and
outstanding
 
Shares of Common Stock   2,990,000,000    9,152,228    2,990,000,000    9,152,228 
Shares of Preferred Stock   10,000,000    
-
    10,000,000    
-
 

 

On March 22, 2022, the Company amended its Certificate of Incorporation and increased the number of authorized shares to 3,000,000,000 with a par value of $0.0001 of which 2,990,000,000 shares shall be Common Stock and 10,000,000 shares shall be preferred stock with a par value of $0.0001.

 

There were no shares of preferred stock of the Company, par value $0.0001 per share (“Preferred Stock”) outstanding at September 30, 2024, and December 31, 2023.

 

Each share of Common Stock is entitled to receive dividends, participate in the distribution of the Company’s net assets upon liquidation, and to receive notices of participation and vote (at one vote per share of Common Stock) at the general meetings of the Company on any matter upon which the general meeting is authorized.

 

On April 23, 2024, the Company received notice from FINRA that the Name Change and the Reverse Stock Split had been announced on FINRA’s daily list and would take effect at market open on the Market Effective Date. Accordingly, the FINRA corporate action to effect the Name Change and the Reverse Stock Split is now completed. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented. 

 

During the three-month period between June 2024 through July 2024, the Company received a total of $85 on account of 154,545 shares of Common Stock, to be issued by the Company to three investors, at a price per share of $0.55.

 

12

 

 

CHARGING ROBOTICS INC.

(FORMERLY FUEL DOCTOR HOLDINGS, INC.)

NOTES TO THE condensed CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands except share and per share data

(UNAUDITED)

 

NOTE 6 – COMMON STOCK AND PREFERRED STOCK (CONT.)

 

  b. Warrants:

 

  (i) Pursuant to the Acquisition (as defined in Note 1), the Company issued the previous shareholders of CR Israel 6,150,000 warrants exercisable upon the Company achieving each of the three (3) performance milestones (collectively, the “Earn Out Milestones”) as follows:

 

  In-house demonstration for automatic robotic charging of an electric vehicle – until December 31, 2025.

 

  Conditional purchase order for first system for automatic car parks – until December 31, 2025.

 

  Commercial agreement for pilot with an organization which was approved by the board – until December 31, 2025.

 

All Earn Out Milestones shall immediately accelerate upon the Company uplisting to the Nasdaq stock exchange.

 

  (ii) On June 20, 2024, the Company issued Automax Motors Ltd. a warrant to purchase 122,831 shares of Common Stock (the “Automax Warrant”). The exercise price of the Automax Warrant was set at $12.82 per share, and the expiry date of the Automax Warrant is September 20, 2027. The fair value of the Automax Warrant granted was $19, using the Black-Scholes option pricing model using the following assumptions:

 

  (iii) A summary of warrant activity during the period is as follows:

 

   Number   Average
weighted
exercise price
 
         
Warrants outstanding at December 31, 2023   6,150,000   $0.00 
Warrant Granted (iv)   122,831    12.82 
Warrants outstanding at September 30, 2024   6,272,831   $0.25 
           
Warrants exercisable at September 30, 2024   122,831   $12.82 

 

  c. Options in CR Israel

 

On February 1, 2022, CR Israel issued 4 options to Ben Gurion University (the “BGU Options”) with an exercise price of $0.01. The BGU Options expire on January 1, 2032. The fair value of the BGU Options granted was $30, using the Black-Scholes option pricing model using the following assumptions:

 

    January
2022
 
CR Israel share price   $ 7,410  
CR Israel Exercise price   $ 0.01  
Dividend yield     0 %
Risk-free interest rate     0.48 %
Expected term (in years)     10  
Volatility     75 %

 

For the nine months ended September 30, 2024, the Company recorded $4 in share-based compensation expenses in respect of the BGU Options (as compared to during the nine months ended September 30, 2023, which was - $9).

 

NOTE 7 – SUBSEQUENT EVENTS

 

The Company evaluated all other events or transactions that occurred through November 13, 2024. The Company determined that it does not have any other subsequent event requiring recording or disclosure in the financial statements for the nine months ended September 30, 2024, other than described below: 

 

13

 

 

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated financial statements (and notes related thereto) and other more detailed financial information appearing elsewhere in this Quarterly Report on Form 10-Q. Consequently, you should read the following discussion and analysis of our financial condition and results of operations together with such financial statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis are set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the “Risk Factors” section of our most recent Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute “forward-looking” statements.

 

All information in this Quarterly Report on Form 10-Q relating to shares or price per share reflects the 1-for-150 reverse stock split effected by us on August 28, 2023, with the shares beginning trading on a post-split basis on the OTC Market on April 23, 2024.

 

OVERVIEW OF OUR PERFORMANCE AND OPERATIONS

 

Recent Developments

 

Our current product, which we are pilot testing with an Automated Parking System (“APS”) supplier in Israel, is a system that wirelessly charges electric vehicles (“EVs”) in APSs. Upon arrival at the APS, the driver parks the EV on a plate used by the APS to transport the EV to the final parking location. The EV remains on the plate until it is retrieved by the APS and the driver enters the EV departs. When a driver parks an EV on these charging plates, they connect a regular charging cable to a socket installed on the plate, at which point the plate moves through the APS via conveyors and elevators to the parking location. Our system is installed in two parts. The electricity receiving component is installed on the plate and consists of a receiving coil and supporting electronics and a socket where the driver connects a cable to the charging socket of the EV. The system’s transmitting component is installed in the APS facility and consists of a transmitting coil and the supporting electronics. As the driver parks the EV and connects the cable from the plate to the EV, he initiates that charging using our mobile application. Once initiated, the system goes into standby mode. Upon the plate arriving at its final parking location, charging of the EV begins. When the plate and EV are in the final parking position, the transmitting coil and the receiving coil are in proximity and by way of electromagnetic induction, electricity passes from the stationary part (transmitting) of the system to the moving (receiving) part of the system. This enables the charging of EVs in places where drivers can not enter and manually connect a plug.

 

Although we have decided to currently focus on the solution for APSs, longer term future products will include the robotic solutions on which the Company was founded. We have succeeded in developing a tethered robotic solution. This robot was intended to charge an EV of a disabled driver and offer an automatic method for wireless charging of EVs. This solution will offer a big benefit for disabled drivers who have difficulty using a regular plug-and-cable-based charger. For these drivers, it is merely impossible to exit the EV, go to the charger, take the cable and connect the plug to the EV. Using our solution, charging will be performed automatically using the tethered robot. As the driver parks the EV, that robot will recognize the EV and will automatically navigate under the EV and charge it wirelessly. For this we have developed a patent-pending technology to navigate to the EV using data obtained by lidar (laser-based) sensors viewing only the EV’s wheels.

 

The Company concluded a pilot testing project of its product with an Israeli company that installs and operates APSs. This pilot project was partially funded by the Israeli Innovation Authority. Based on this pilot test, the Company has begun developing its next generation product with new features and fixes that will make it more suitable for mass production and sales. This next generation of the Company’s product is expected to be ready for commercialization in January 2025. The Company’s expected timeframe to receive regulatory approval for this product from the Israel Standardization Institute has been slightly delayed, with the new expected timing for approval to occur by April 2025.

 

14

 

 

The purchase order received from an APS provider in Israel for installation of multiple systems in June 2025 was delayed and the systems are now expected to be installed towards the end of 2025. We are also in discussions with three other APS providers in Israel. The combined forecast from these customers and potential customers is installation of approximately thirty systems by the end of 2024. We see this growth as indicative of a favorable response from the market to our systems.

 

In order to prepare to meet this increased market demand, we are in the process of establishing subcontractor-based production capabilities, working on increasing our work force and sourcing office and R&D spaces. We have located an office and production space and plan to move our activities to this location by December 31, 2024.

 

On April 23, 2024, the Company received notice from FINRA that the Name Change and the Reverse Stock Split was announced on FINRA’s daily list and would take effect at market open on the Market Effective Date. Accordingly, the FINRA corporate action to effect the Name Change and the Reverse Stock Split is now completed. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in this management’s discussion and analysis of financial condition and results of operations. 

 

Hamas-Israel War

 

In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations in parallel to their continued rocket and terror attacks. In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with the Hezbollah terror organization based in Lebanon, and more recently, to the south of Israel, with the Houthi terror organization in Yemen. The hostilities with Hezbollah have escalated recently, prompting Israel to send its ground forces into southern Lebanon to destroy terrorist positions and infrastructure used by Hezbollah for attacks on northern and central Israel, which had caused the displacement of residents in northern Israel since early in the war. There is a risk that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries will join the hostilities against Israel. In addition, Iran has entered the conflict against Israel, shooting ballistic missiles at Israel twice during the current war (on April 13, 2024 and October 1, 2024). Iran is furthermore widely believed to be developing nuclear weapons, with which it has threatened Israel. Such clashes may escalate into a greater regional conflict.

 

Results of Operations for the nine months ended September 30, 2024 and September 30, 2023

 

Revenues

 

We have generated revenues of $0 and $0 for the nine months ended September 30, 2024, and September 30, 2023, respectively.

 

Operating expenses

 

Operating expenses for the nine months ended September 30, 2024, were $546 thousand compared with $504 thousand for the nine months ended September 30, 2023. The increase in operating expenses in 2024 is due to an increase in general and administrative expenses. Research and development expenses for the nine months ended September 30, 2024, were $226 thousand, compared to $294 thousand for the nine months ended September 30, 2023. General and administrative expenses increased by $110 thousand, from $210 thousand for the nine months ended September 30, 2023, to $320 thousand for the nine months ended September 30, 2024. The increase is due to increased business and other operational activity in the Company, including the completion of our first pilot project with Parkomot.

 

15

 

 

Results of Operations of the Company for the three months ended September 30, 2024 and September 30, 2023

 

Revenues

 

We have generated revenues of $0 and $0 for the three months ended September 30, 2024 and September 30, 2023, respectively.

 

Operating expenses

 

Operating expenses for the three months ended September 30, 2024, were $185 thousand compared with $272 thousand for the three months ended September 30, 2023. Research and development expenses for the three months ended September 30, 2024, amounted to $78 thousand, compared to $145 thousand for the three months ended September 30, 2023. The decrease is due mainly to a decrease in subcontractor expenses. General and administrative expenses decreased by $20 thousand, from $127 thousand for the three months ended September 30, 2023, to $107 thousand for the three months ended September 30, 2024.

 

Liquidity and Capital Resources

 

As of September 30, 2024, and December 31, 2023, the Company’s cash balance was $6 thousand and $8 thousand, respectively.

 

As of September 30, 2024, and December 31, 2023, the Company’s total assets were $271 thousand and $323 thousand, respectively.

 

As of September 30, 2024, the Company had total liabilities of $905 thousand, that consisted of $289 thousand in accounts payable and accrued liabilities, $160 thousand in related parties, $85 thousand in receipt upon investment in our shares, $31 thousand in deferred revenues and $340 thousand in short term loans.

 

As of December 31, 2023, the Company had total liabilities of $397 thousand, that consisted of $220 thousand in accounts payable and accrued liabilities, $98 thousand in related parties, $49 thousand in deferred revenues, and $30 thousand in short term loans.

 

As of September 30, 2024, the Company had a negative working capital of $849 thousand. As of December 31, 2023, the Company had negative working capital of $297 thousand.

 

Working Capital and Cash Flows (in thousands of U.S. Dollars)

 

Working Capital

 

   September 30,
2024
   December 31,
2023
 
         
Current assets  $25   $51 
Current liabilities   874    348 
Working capital deficit  $(849)  $(297)

 

Cash Flows

 

    September 30,
2024
    September 30,
2023
 
             
Cash flow used generated in operating activities   $ (375 )   $ (511 )
Cash flow generated (used) in investing activities     (4 )     3  
Cash flows from financing activities     377       591  
Net increase (decrease) in cash during the period   $ (2   $ 83  

 

16

 

 

Cash flows from operating activities

 

During the nine months ended September 30, 2024, we had negative cash flow from operations of $375 thousand compared to a negative cashflow of $511 thousand for the nine months ended September 30, 2023.

 

Cash flows from investing activities

 

During the nine months ended September 30, 2024, we had negative cash flow from investing activities of $4 thousand, compared to a cashflow of $3 thousand for the nine months ended September 30, 2023.

 

Cash flows from financing activities

 

During the nine months ended September 30, 2024, we had a positive cash flow from financing activities of $377 thousand, compared to a cashflow of $592 thousand for the nine months ended September 30, 2023.

 

Critical Accounting Policies

 

Going Concern

 

We have not attained profitable operations and are dependent upon the continued financial support from our shareholders, the ability to raise equity or debt financing, and the attainment of profitable operations from our future business. These factors raise substantial doubt regarding our ability to continue as a going concern.

 

Our ability to continue as a going concern is dependent upon our ability to generate future profitable operations and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due.

 

The Company, as of September 30, 2024, had $6 thousand in cash and has not generated any revenues from operations to date. For the nine months ended September 30, 2024, and September 30, 2023, our operating expenses amounted to $546 thousand and $504 thousand, respectively. In the previous two fiscal years our operating expenses were $740 thousand and $753 thousand for the years ended December 31, 2023 and December 31, 2022, respectively.

 

The Company continues to rely on borrowings and financings. In the next 12 months we expect to incur expenses equal to approximately $1 million to advance Charging Robotics’ product and expenses related to legal, accounting, audit and other professional service fees incurred in relation to the Company’s status as a U.S. reporting company. These conditions raise substantial doubt about our ability to continue as a going concern. The Company is currently devoting its efforts to raise further funds. The Company’s ability to continue as a going concern is dependent upon our ability to develop additional sources of capital, locate and complete a merger with another company, and ultimately, achieve profitable operations. There is no assurance that we will in fact have access to additional capital or financing as a public company.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

Default on Notes

 

There are currently no notes in default.

 

Other Contractual Obligations

 

As of the year ended December 31, 2023 and the nine months ended September 30, 2024, we did not have any contractual obligations, other than those already disclosed in our most recent annual report on Form 10-K.

 

17

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 3.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures include, without limitation, means controls and other procedures that are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and (ii) accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, because of the Company’s limited resources and lack of employees, management, including our chief executive officer and chief financial officer, concluded that our disclosure controls and procedures were ineffective as of September 30, 2024 and as of the date of this filing, November 13, 2024.

 

Management has identified control deficiencies regarding inadequate accounting resources, the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of the Company’s accounting outsourced staff may prevent adequate controls in the future due to the cost/benefit of such remediation. 

 

To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

 

These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our consolidated financial statements may not be prevented or detected on a timely basis. In light of this material weakness, we performed additional analyses and procedures in order to conclude that our consolidated financial statements for the quarter ended September 30, 2024 included in this Quarterly Report on Form 10-Q were fairly stated in accordance with GAAP. Accordingly, management believes that despite our material weaknesses, our consolidated financial statements for the quarter ended September 30, 2024 are fairly stated, in all material respects, in accordance with GAAP.

 

Limitations on Effectiveness of Controls and Procedures

 

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

Changes in Internal Control over Financial Reporting

 

No changes in the Company’s internal control over financial reporting have come to management’s attention during the Company’s last fiscal quarter that have materially affected, or are likely to materially affect, the Company’s internal control over financial reporting.

  

18

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.  

 

We are not aware of any pending or threatened legal proceedings involving our Company or its assets.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.  

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

During the quarter ended September 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).

 

ITEM 6. EXHIBITS.

 

Exhibit

Number

  Description
31.1   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2   Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
EX-101.INS   Inline XBRL Instance Document*
EX-101.SCH   Inline XBRL Taxonomy Extension Schema Document*
EX-101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document*
EX-101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document*
EX-101.LAB   Inline XBRL Taxonomy Extension Labels Linkbase Document*
EX-101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document*
EX-104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*

 

* The XBRL related information in Exhibit 101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

 

19

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CHARGING ROBOTICS INC.
     
Date: November 13, 2024 By: /s/ Hovav Gilan
    Name: Hovav Gilan
    Title: Chief Executive Officer
      (Principal Executive Officer)
     
  By: /s/ Gadi Levin
    Name:  Gadi Levin
    Title: Chief Financial Officer
      (Principal Financial and Accounting Officer)

 

 

20

 

NONE false --12-31 Q3 0001459188 true 0001459188 2024-01-01 2024-09-30 0001459188 2024-11-13 0001459188 2024-09-30 0001459188 2023-12-31 0001459188 us-gaap:RelatedPartyMember 2024-09-30 0001459188 us-gaap:RelatedPartyMember 2023-12-31 0001459188 2024-07-01 2024-09-30 0001459188 2023-07-01 2023-09-30 0001459188 2023-01-01 2023-09-30 0001459188 us-gaap:CommonStockMember 2023-12-31 0001459188 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001459188 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-12-31 0001459188 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001459188 us-gaap:RetainedEarningsMember 2023-12-31 0001459188 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-01-01 2024-09-30 0001459188 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001459188 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001459188 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001459188 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001459188 us-gaap:CommonStockMember 2024-09-30 0001459188 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001459188 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-09-30 0001459188 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001459188 us-gaap:RetainedEarningsMember 2024-09-30 0001459188 us-gaap:CommonStockMember 2022-12-31 0001459188 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001459188 us-gaap:DeferredCompensationShareBasedPaymentsMember 2022-12-31 0001459188 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001459188 us-gaap:RetainedEarningsMember 2022-12-31 0001459188 2022-12-31 0001459188 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001459188 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001459188 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-01-01 2023-09-30 0001459188 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001459188 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001459188 us-gaap:CommonStockMember 2023-09-30 0001459188 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001459188 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-09-30 0001459188 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001459188 us-gaap:RetainedEarningsMember 2023-09-30 0001459188 2023-09-30 0001459188 fdocd:ChargingRoboticsMember 2023-04-07 0001459188 us-gaap:PrivatePlacementMember 2023-04-06 2023-04-06 0001459188 us-gaap:CommonStockMember 2023-04-06 0001459188 2023-04-06 2023-04-06 0001459188 2023-11-22 2023-11-22 0001459188 country:IL 2023-01-01 2023-12-31 0001459188 country:IL 2024-02-14 2024-02-14 0001459188 fdocd:RoboticsMember 2021-04-24 0001459188 2021-04-01 2021-04-24 0001459188 fdocd:RevoltzMember 2022-07-28 0001459188 fdocd:RevoltzMember 2024-01-01 2024-09-30 0001459188 2023-01-01 2023-12-31 0001459188 fdocd:XyloLoanMember 2023-01-01 0001459188 fdocd:XyloLoanMember 2022-01-01 2022-12-31 0001459188 2023-04-04 0001459188 fdocd:XyloLoanMember 2023-04-04 0001459188 2023-04-04 2023-04-04 0001459188 2021-10-01 0001459188 2021-10-01 2021-10-01 0001459188 srt:ChiefExecutiveOfficerMember 2024-09-30 0001459188 srt:ChiefExecutiveOfficerMember 2023-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCEOMember 2024-07-01 2024-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCEOMember 2023-07-01 2023-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCEOMember 2024-01-01 2024-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCEOMember 2023-01-01 2023-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCFOMember 2024-07-01 2024-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCFOMember 2023-07-01 2023-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCFOMember 2024-01-01 2024-09-30 0001459188 fdocd:KeyManagementMember fdocd:ConsultingFeesCFOMember 2023-01-01 2023-09-30 0001459188 fdocd:KeyManagementMember fdocd:DirectorsCompensationMember 2024-07-01 2024-09-30 0001459188 fdocd:KeyManagementMember fdocd:DirectorsCompensationMember 2023-07-01 2023-09-30 0001459188 fdocd:KeyManagementMember fdocd:DirectorsCompensationMember 2024-01-01 2024-09-30 0001459188 fdocd:KeyManagementMember fdocd:DirectorsCompensationMember 2023-01-01 2023-09-30 0001459188 fdocd:ConsultingFeesCEOMember 2024-01-01 2024-09-30 0001459188 fdocd:ConsultingFeesCEOMember 2023-01-01 2023-12-31 0001459188 fdocd:ConsultingFeesCFOMember 2024-01-01 2024-09-30 0001459188 fdocd:ConsultingFeesCFOMember 2023-01-01 2023-12-31 0001459188 fdocd:DirectorsMember 2024-01-01 2024-09-30 0001459188 fdocd:DirectorsMember 2023-01-01 2023-12-31 0001459188 fdocd:RevoltzMember 2024-01-01 2024-09-30 0001459188 fdocd:RevoltzMember 2023-01-01 2023-12-31 0001459188 fdocd:XyloMember 2024-01-01 2024-09-30 0001459188 fdocd:XyloMember 2023-01-01 2023-12-31 0001459188 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0001459188 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001459188 fdocd:ShareCapitalMember us-gaap:CommonStockMember 2022-03-22 0001459188 fdocd:ArticlesOfIncorporationMember us-gaap:CommonStockMember 2022-03-22 0001459188 fdocd:ArticlesOfIncorporationMember 2022-03-22 0001459188 us-gaap:PreferredStockMember 2022-03-22 0001459188 us-gaap:CommonStockMember 2022-03-22 0001459188 us-gaap:InvestorMember 2024-06-01 2024-07-31 0001459188 2024-07-31 0001459188 us-gaap:InvestorMember 2024-09-30 0001459188 fdocd:AutomaxMotorsLtdMember 2024-06-20 0001459188 fdocd:BGUOptionsMember 2022-02-01 2022-02-01 0001459188 fdocd:AcquisitionAgreementMember 2024-01-01 2024-09-30 0001459188 us-gaap:CommonStockMember 2024-09-30 0001459188 us-gaap:CommonStockMember 2023-12-31 0001459188 us-gaap:PreferredStockMember 2024-09-30 0001459188 us-gaap:PreferredStockMember 2023-12-31 0001459188 2022-01-31 0001459188 2022-01-01 2022-01-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:ILS

 

Exhibit 31.1

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Hovav Gilan, Chief Executive Officer, of Charging Robotics Inc. (the “Company”), certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of the Company for the quarter ended September 30, 2024;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this quarterly report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the Company and have:

 

  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is prepared;

 

  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this quarterly report based on such evaluation; and

 

  d. disclosed in this quarterly report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of Company’s board of directors (or persons performing the equivalent functions):

 

  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

  b. any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

Date: November 13, 2024  
     
By: /s/ Hovav Gilan  
  Hovav Gilan  
  Chief Executive Officer  

 

 

 

 

Exhibit 31.2

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Gadi Levin, Principal Financial Officer of Charging Robotics Inc. (the “Company”), certify that:

  

1. I have reviewed this quarterly report on Form 10-Q of the Company for the quarter ended September 30, 2024;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this quarterly report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the Company and have:

 

  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is prepared;

 

  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this quarterly report based on such evaluation; and

 

  d. disclosed in this quarterly report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of Company’s board of directors (or persons performing the equivalent functions):

 

  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

  b. any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

  

Date: November 13, 2024  
   
By: /s/ Gadi Levin  
  Gadi Levin  
  Principal Financial Officer  

 

 

 

 

Exhibit 32.1

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350

 

I, Hovav Gilan, Chief Executive Officer of Charging Robotics Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, to my knowledge that:

 

1. the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 13, 2024  
   
By: /s/ Hovav Gilan  
  Hovav Gilan  
  Chief Executive Officer  

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

  

 

 

 

Exhibit 32.2

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350

 

I, Gadi Levin, Principal Financial Officer of Charging Robotics Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, to my knowledge that:

 

1. the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 13, 2024  
   
By: /s/ Gadi Levin  
  Gadi Levin  
  Principal Financial Officer  

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

v3.24.3
Cover - shares
9 Months Ended
Sep. 30, 2024
Nov. 13, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Sep. 30, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Information [Line Items]    
Entity Registrant Name CHARGING ROBOTICS INC.  
Entity Central Index Key 0001459188  
Entity File Number 000-56253  
Entity Tax Identification Number 26-2274999  
Entity Incorporation, State or Country Code DE  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Incorporation, Date of Incorporation Mar. 25, 2008  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 20 Raul Wallenberg Street  
Entity Address, City or Town Tel Aviv  
Entity Address, Country IL  
Entity Address, Postal Zip Code 6971916  
Entity Phone Fax Numbers [Line Items]    
City Area Code (+972)  
Local Phone Number 54 642-0352  
Entity Listings [Line Items]    
Title of 12(b) Security N/A  
No Trading Symbol Flag true  
Security Exchange Name NONE  
Entity Common Stock, Shares Outstanding   9,152,228
v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash $ 6 $ 8
Other accounts receivable 19 43
Total current assets 25 51
Non current assets:    
Intangible asset 104 100
Investment in an affiliate (Note 4) 78 110
Loan to an affiliate (Note 4) 64 62
Total non current assets 246 272
TOTAL ASSETS 271 323
Current liabilities:    
Accounts payable 92 104
Other current liabilities 197 116
Receipt on account of shares 85
Short term loans 340 30
Total current liabilities 874 348
Non-current liabilities:    
Deferred revenues 31 49
Total liabilities 905 397
Stockholders’ deficit (Note 6)    
Preferred shares of the Company, par value $0.0001 per share, 10,000,000 shares authorized, 0 shares issued and outstanding on each of September 30, 2024 and December 31, 2023
Common Stock, par value $0.0001, 2,990,000,000 shares authorized, 9,152,228 shares issued and outstanding on each of September 30, 2024 and December 31, 2023 1 1
Additional paid-in capital 1,817 1,817
Foreign currency transaction reserve (29) (27)
Reserve from share-based compensation transactions 123 101
Accumulated deficit (2,546) (1,966)
Total stockholders’ deficit (634) (74)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 271 323
Related Party    
Current liabilities:    
Related parties (Note 5) $ 160 $ 98
v3.24.3
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred shares, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred shares, shares authorized 10,000,000 10,000,000
Preferred shares, shares issued 0 0
Preferred shares, outstanding 0 0
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 2,990,000,000 2,990,000,000
Common stock, shares issued 9,152,228 9,152,228
Common stock, shares outstanding 9,152,228 9,152,228
v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Research and development costs $ 78 $ 145 $ 226 $ 294
General and administrative costs 107 127 320 210
Operating loss (185) (272) (546) (504)
Financial expenses (7) (4)
Net loss (192) (272) (550) (504)
Share in losses of affiliate (7) (14) (30) (24)
Net loss for the period (199) (286) (580) (528)
Other comprehensive loss 1 (20) (2) (20)
Net loss and comprehensive loss for the period $ (198) $ (306) $ (582) $ (548)
Basic loss per common share (in Dollars per share) $ (0.02) $ (0.03) $ (0.06) $ (0.09)
Diluted loss per common share (in Dollars per share) $ (0.02) $ (0.03) $ (0.06) $ (0.09)
Weighted average common shares outstanding (in Shares) [1] 9,152,228 9,152,228 9,152,228 5,796,304
[1] On April 23, 2024, the Company received notice from FINRA that the Reverse Stock Split has been announced on FINRA’s daily list and will take effect at market open on April 24, 2024 (the “Market Effective Date”). Accordingly, the FINRA corporate action to effect the Reverse Stock Split is now completed. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.
v3.24.3
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Common Stock
Additional Paid in capital
Stock-based compensation
Accumulated other comprehensive loss
Accumulated Deficit
Total
Balance at Dec. 31, 2022 $ 741 $ 91 $ (12) $ (1,188) $ (368)
Balance (in Shares) at Dec. 31, 2022 182          
Issuance of warrant          
Exercise of options 91 9 100
Exercise of options (in Shares) 27          
Issuance of shares in respect of converted loan 509 509
Issuance of shares in respect of converted loan (in Shares) 51          
Effect of reverse merger $ 1 (25) (24)
Effect of reverse merger (in Shares) 8,241,968          
Issuance of shares in respect of private placement 501 501
Issuance of shares in respect of private placement (in Shares) 910,000          
Net comprehensive loss for the period (20) (528) (548)
Balance at Sep. 30, 2023 $ 1 1,817 100 (32) (1,716) 170
Balance (in Shares) at Sep. 30, 2023 9,152,228          
Balance at Dec. 31, 2023 $ 1 1,817 101 (27) (1,966) (74)
Balance (in Shares) at Dec. 31, 2023 9,152,228          
Issuance of warrant     18     18
Share-based payment reserve 4 4
Net comprehensive loss for the period (2) (580) (582)
Balance at Sep. 30, 2024 $ 1 $ 1,817 $ 123 $ (29) $ (2,546) $ (634)
Balance (in Shares) at Sep. 30, 2024 9,152,228          
v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (580) $ (528)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based payment expenses 4 9
Share in losses of affiliate 30 24
Interest expenses 16
Changes in operating assets and liabilities:    
Decrease (increase) in other accounts receivable 24 25
Increase (decrease) in related parties 62 26
Increase (decrease) in accounts payable (12) (99)
Increase in other accounts payable and accrued expenses 81 32
Net cash used in operating activities (375) (511)
CASH FLOWS USED IN INVESTING ACTIVITIES:    
Effect of reverse merger (4) 3
Net cash used in investing activities (4) 3
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of shares in respect of a private placement 500
Proceeds from short term loans received 292
Proceeds on account of shares 85
Proceeds from exercise of options 91
Net cash provided by financing activities 377 591
Net increase (decrease) in cash (2) 83
Effect of changes in foreign exchange rates 1
Cash at beginning of period 8 27
Cash at end of period 6 111
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Interest
Franchise taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:    
Issuance of shares to in respect of converted loan 509
Issuance of warrants in respect of deferred revenue $ 18
v3.24.3
General
9 Months Ended
Sep. 30, 2024
General [Abstract]  
GENERAL

NOTE 1 – GENERAL

 

Charging Robotics Inc. (formerly Fuel Doctor Holdings, Inc.) (the “Company”) was incorporated in the State of Delaware on March 25, 2008, as Silver Hill Management Services, Inc. On August 24, 2011, the Company amended its Certificate of Incorporation and changed its name to Fuel Doctor Holdings, Inc, and on April 23, 2024, the Company changed its name to Charging Robotics Inc.

 

On March 28, 2023, the Company entered into a Securities Exchange Agreement (the “Acquisition Agreement”) with the stockholders of Charging Robotics Ltd. (“CR Israel”). Pursuant to the Acquisition Agreement, at the closing, which occurred on April 7, 2023 (the “Closing”), the Company acquired 100% of the issued and outstanding stock of CR Israel (the “Acquisition”), making CR Israel a wholly owned subsidiary of the Company.

 

CR Israel was formed in February 2021, as an Israeli corporation, with the main goal of developing an innovative wireless electric vehicles (EV) charging technology. At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer electricity wirelessly. This module can be used for various products such as robotic and stationary platforms. The robotic platform includes a component which is small enough to fit under the vehicle, and which automatically positions itself for maximum-efficiency charging, and upon charging completion automatically returns to its docking station. CR Israel also developed a Wireless EV Charging System for automatic parking lots based on our wireless electricity transfer module.

 

On April 6, 2023, the Company issued a total of 910,000 newly issued shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) in respect of a private placement for total proceeds of $500.

 

On November 22, 2023, the Company announced that CR Israel received approval for funding from the Israel Innovation Authority (the “IIA”) for a pilot project to include installing and demonstrating its solution for wireless charging of electric vehicles (EVs) in automated parking systems (“APS”). The total approved budget for this project was approximately $445, of which the IIA would finance 50%. The Company is now engaged in the pilot project to implement the solution in an APS in Tel Aviv. In December 2023, CR Israel received $77 from the IIA, and on February 14, 2024, CR Israel received an additional $33 from the IIA.

 

On August 28, 2023, the Company filed an amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”), to (i) change its name to Charging Robotics Inc. (the “Name Change”); and (ii) effect a one-for-one hundred fifty reverse stock split (the “Reverse Stock Split”) of its outstanding shares of Common Stock.

 

On August 28, 2023, the Company submitted an Issuer Company-Related Action Notification Form to the Financial Industry Regulatory Authority, Inc. (“FINRA”) regarding the Name Change and Reverse Stock Split.

 

On April 23, 2024, the Company received notice from FINRA that the Name Change and the Reverse Stock Split was announced on FINRA’s daily list and would take effect at market open on the Market Effective Date. Accordingly, the FINRA corporate action to effect the Name Change and the Reverse Stock Split was completed on April 23, 2024.

 

Basis of presentation of the financial statements:

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments consisting of a normal recurring nature which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented.

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report for the year ended December 31, 2023, filed with the SEC on March 12, 2024. The interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

v3.24.3
Unaudited Interim Condensed Financial Statements
9 Months Ended
Sep. 30, 2024
Unaudited Interim Condensed Financial Statements [Abstract]  
UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

NOTE 2 – UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

 

The financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP).

 

  a. Use of estimates:

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to share-based compensation and the Company’s ability to continue as a going concern.

 

  b. Financial statements in U.S. dollars:

 

The costs of the Company are denominated in United States dollars (“dollars”). Some of the costs in our Israeli associate are incurred in New Israeli Shekels (NIS), however the selling prices will be linked to the Company’s price list which will be determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and its subsidiary operates. Thus, the dollar is the Company’s and its subsidiary functional and reporting currency.

 

Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the statements of operations as appropriate.

 

The functional currency of the affiliate company is the NIS and therefore foreign exchange differences are charged to the other comprehensive profit and loss.

 

  c. Cash and cash equivalents:

 

Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.

 

  d. Investment in affiliated companies

 

Affiliated company is company held to the extent of 20% or more (which are not subsidiary), or company less than 20% held, which the Company can exercise significant influence over operating and financial policy of the affiliate.

 

The investment in the affiliated company is accounted for by the equity method under ASC Subtopic 323-30, “Investments - Equity Method and Joint Ventures: Partnerships, Joint Ventures, and Limited Liability Entities”. Upon initial recognition, the cost of investment is based on the direct costs of acquiring the investment including amounts incurred on behalf of the investee.

 

Following the acquisition, the Company recognizes its proportionate share of the affiliated company’s net income or loss after the date of investment. When previous losses have reduced the Common Stock investment account to zero, the Company continues to report its share of equity method losses in its statement of operations to the extent of and as an adjustment to other investments in the investee such as debt securities, long term loans or advances, if any. Such additional equity method losses are applied to the other investments based on the seniority of the other investments (priority in liquidation) and the percentage ownership interest in each type of other investment the Company holds (the ‘relative holdings approach’).

 

  e. Impairment of long-lived assets:

 

The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the year ended December 31, 2023, no impairment losses were recorded.

 

  f. Concentration of credit risks:

 

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings.

 

The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.

 

  g. Research and development expenses:

 

Research and development costs are charged to the statement of operations as incurred.

 

  h. Fair value of financial instruments:

 

ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  Level 1 Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.
       
  Level 2 Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
       
  Level 3 Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying amounts of cash and cash equivalents, other current assets, accounts payables and current liabilities approximate their fair value due to the short-term maturity of such instruments.

 

  i. Income Tax:

 

The Company account for income taxes in accordance with ASC 740, “Income Taxes” which prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will be realized. Based on ASC 740, a two-step approach is used to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.

 

The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2023, no liability for unrecognized tax positions has been recorded. Accordingly, no interest or penalties related to uncertain tax positions are recorded, either. It is the Company’s policy that any interest or penalties associated with unrecognized tax positions would be reflected in income tax expense.

 

  j. Contingencies:

 

The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

  k. Stock-based payments:

 

The Company measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.

 

Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, “Equity-Based Payments to Non-Employees”.

 

For the nine months ended September 30, 2024, the Company recorded $4, in share-based compensation (see note 5(b)).

 

Basis of Presentation and Principles of Consolidation:

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”)

 

All intercompany accounts and transactions have been eliminated in consolidation.

 

Unaudited Interim Financial Information

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

 

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the nine months ended September 30, 2024, are not necessarily indicative of the results for the year ending December 31, 2024, or for any future period.

 

Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2023, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 12, 2024 (the “2023 Annual Report”).

 

As of September 30, 2024, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2023 Annual Report.

v3.24.3
Going Concern
9 Months Ended
Sep. 30, 2024
Going Concern [Abstract]  
GOING CONCERN

NOTE 3 – GOING CONCERN

 

The condensed consolidated financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred a loss since inception resulting in an accumulated deficit of $1,966, as of December 31, 2023, and $2,546, as of September 30, 2024, and further losses are anticipated in the development of its business. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources and through additional raises of capital.

 

Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors. However, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

v3.24.3
Investment in Affiliated Company
9 Months Ended
Sep. 30, 2024
Investment in Affiliated Company [Abstract]  
INVESTMENT IN AFFILIATED COMPANY

NOTE 4 – INVESTMENT IN AFFILIATED COMPANY

 

  a. On April 24, 2021, CR Israel invested $250 and purchased 19.99% of the share capital of Revoltz Ltd (“Revoltz”), an Israeli private company focusing on research, development and production of micro-mobility vehicles for the urban environment for the business and the private markets.

 

  b. On July 28, 2022, CR Israel entered into a convertible loan agreement with Revoltz pursuant to which CR Israel was required to invest an amount of $60 in Revoltz (the “Loan Principal Amount”). In addition, CR Israel provided Revoltz further lending of up to $340 (the “Additional Amount”, and together with the Loan Principal, the “Total Loan Amount”). The Total Loan Amount shall carry interest at the minimum rate prescribed by Israeli law.

 

The Total Loan Amount shall be converted into shares of Revoltz, upon the occurrence of any of the following events (each a “Trigger Event”):

 

  i) The consummation of funding by Revoltz of an aggregate amount of $1,000 at a pre-money Revoltz valuation of at least $7,000 (in the form of SAFE, equity or otherwise);

 

  ii) Revoltz has generated an aggregate of $1,000 or more in revenue.

 

In the event that a Trigger Event shall not have occurred on or prior to the 24-month anniversary of the date on which the Loan Principal Amount is actually extended to Revoltz, the Loan shall be due and repayable by Revoltz to the Company.  

 

On September 30, 2024, the balance of the Loan Principal Amount was $64.  

 

  c. The following table summarizes the equity method accounting for the investment in affiliated company:

 

Balance January 1, 2023  $152 
Share in losses of affiliated company   (27)
Foreign currency translation   (15)
Balance December 31, 2023  $110 
Share in losses of affiliated company   (30)
Foreign currency translation   (2)
Balance September 30, 2024  $78 
v3.24.3
Related Parties
9 Months Ended
Sep. 30, 2024
Related Parties [Abstract]  
RELATED PARTIES

NOTE 5 – RELATED PARTIES

 

  a. In support of the Company’s efforts and cash requirements, the Company may rely on advances from related parties until such a time that the Company can support its operations or attains adequate financing through sales of stock or traditional debt financing. There is no formal written commitment for continued support by related parties.

 

  (i) The compensation to key management personnel for employment services they provide to the Company is as follows:  

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2024   2023   2024   2023 
Consulting Fees – CEO  $20   $21   $60   $63 
Consulting Fees - CFO  $9   $12   $27   $32 
Directors’ compensation  $21   $21   $63   $42 

 

  (ii) Balances owed to (by) related parties

 

   September 30,   December 31, 
   2024   2023 
Consulting Fees – CEO  $20   $8 
Consulting Fees – CFO   12    8 
Directors   70    27 
Revoltz (see note 4b)   (64)   (62)
Xylo (see note 5c)   57    55 
   $95   $36 

 

  b. The Company currently operates out of an office of a related party free of rent.

 

  c. As of January 1, 2023, CR Israel owed Xylo Technologies Ltd., f/k/a Medigus Ltd., a related party (“Xylo”) $550 (the “Xylo Loan”). The Xylo Loan bears interest in accordance with section 3(i) of the Israeli tax code (2.42% annually during 2022) and no fixed date for repayment has been determined. On January 1, 2023, CR Israel and Xylo signed an agreement to amend the terms of the Xylo Loan (the “Xylo Loan Agreement”). Pursuant to the Xylo Loan Agreement, the interest rate remains unchanged, and the capital and interest was to be repaid in cash or shares, or a combination thereof by June 30, 2023. On April 4, 2023, the Xylo Loan balance owing was $553. $509 of the Xylo Loan was converted into 28 shares of CR Israel and the remaining Xylo Loan balance will be repaid in cash. The Company is in discussions with Xylo to extend the repayment date of the remaining loan balance.

 

  d. On October 1, 2021, CR Israel signed a consulting agreement with the CEO, pursuant to which CR Israel will pay the CEO a monthly fee of NIS 24,700 (approximately $7). Subject to approval of CR Israels’ board of directors (“Board”), the CEO shall be entitled to receive stock options in the Company that will entitle him to own 3% of Charging Robotics. The options will have an exercise price equivalent to a Company valuation of $10,000. As of the date of this report, the options have not been issued as the Board has not yet approved their issuance.

 

During the nine months ended September 30, 2024, the CEO earned $60 (during the nine months ended September 30, 2023 - $63).

v3.24.3
Common Stock and Preferred Stock
9 Months Ended
Sep. 30, 2024
Common Stock and Preferred Stock [Abstract]  
COMMON STOCK AND PREFERRED STOCK

NOTE 6 – COMMON STOCK AND PREFERRED STOCK

 

  a. As of September 30, 2024, and December 31, 2023, the Company’s share capital is composed as follows:

 

   September 30, 2024   December 31, 2023 
   Authorized   Issued and
outstanding
   Authorized   Issued and
outstanding
 
Shares of Common Stock   2,990,000,000    9,152,228    2,990,000,000    9,152,228 
Shares of Preferred Stock   10,000,000    
-
    10,000,000    
-
 

 

On March 22, 2022, the Company amended its Certificate of Incorporation and increased the number of authorized shares to 3,000,000,000 with a par value of $0.0001 of which 2,990,000,000 shares shall be Common Stock and 10,000,000 shares shall be preferred stock with a par value of $0.0001.

 

There were no shares of preferred stock of the Company, par value $0.0001 per share (“Preferred Stock”) outstanding at September 30, 2024, and December 31, 2023.

 

Each share of Common Stock is entitled to receive dividends, participate in the distribution of the Company’s net assets upon liquidation, and to receive notices of participation and vote (at one vote per share of Common Stock) at the general meetings of the Company on any matter upon which the general meeting is authorized.

 

On April 23, 2024, the Company received notice from FINRA that the Name Change and the Reverse Stock Split had been announced on FINRA’s daily list and would take effect at market open on the Market Effective Date. Accordingly, the FINRA corporate action to effect the Name Change and the Reverse Stock Split is now completed. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented. 

 

During the three-month period between June 2024 through July 2024, the Company received a total of $85 on account of 154,545 shares of Common Stock, to be issued by the Company to three investors, at a price per share of $0.55.

 

  b. Warrants:

 

  (i) Pursuant to the Acquisition (as defined in Note 1), the Company issued the previous shareholders of CR Israel 6,150,000 warrants exercisable upon the Company achieving each of the three (3) performance milestones (collectively, the “Earn Out Milestones”) as follows:

 

  In-house demonstration for automatic robotic charging of an electric vehicle – until December 31, 2025.

 

  Conditional purchase order for first system for automatic car parks – until December 31, 2025.

 

  Commercial agreement for pilot with an organization which was approved by the board – until December 31, 2025.

 

All Earn Out Milestones shall immediately accelerate upon the Company uplisting to the Nasdaq stock exchange.

 

  (ii) On June 20, 2024, the Company issued Automax Motors Ltd. a warrant to purchase 122,831 shares of Common Stock (the “Automax Warrant”). The exercise price of the Automax Warrant was set at $12.82 per share, and the expiry date of the Automax Warrant is September 20, 2027. The fair value of the Automax Warrant granted was $19, using the Black-Scholes option pricing model using the following assumptions:

 

  (iii) A summary of warrant activity during the period is as follows:

 

   Number   Average
weighted
exercise price
 
         
Warrants outstanding at December 31, 2023   6,150,000   $0.00 
Warrant Granted (iv)   122,831    12.82 
Warrants outstanding at September 30, 2024   6,272,831   $0.25 
           
Warrants exercisable at September 30, 2024   122,831   $12.82 

 

  c. Options in CR Israel

 

On February 1, 2022, CR Israel issued 4 options to Ben Gurion University (the “BGU Options”) with an exercise price of $0.01. The BGU Options expire on January 1, 2032. The fair value of the BGU Options granted was $30, using the Black-Scholes option pricing model using the following assumptions:

 

    January
2022
 
CR Israel share price   $ 7,410  
CR Israel Exercise price   $ 0.01  
Dividend yield     0 %
Risk-free interest rate     0.48 %
Expected term (in years)     10  
Volatility     75 %

 

For the nine months ended September 30, 2024, the Company recorded $4 in share-based compensation expenses in respect of the BGU Options (as compared to during the nine months ended September 30, 2023, which was - $9).

v3.24.3
Subsequent Events
9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 7 – SUBSEQUENT EVENTS

 

The Company evaluated all other events or transactions that occurred through November 13, 2024. The Company determined that it does not have any other subsequent event requiring recording or disclosure in the financial statements for the nine months ended September 30, 2024, other than described below: 

v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure        
Net Income (Loss) $ (199) $ (286) $ (580) $ (528)
v3.24.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.3
Accounting Policies, by Policy (Policies)
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Use of estimates
  a. Use of estimates:

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to share-based compensation and the Company’s ability to continue as a going concern.

Financial statements in U.S. dollars
  b. Financial statements in U.S. dollars:

The costs of the Company are denominated in United States dollars (“dollars”). Some of the costs in our Israeli associate are incurred in New Israeli Shekels (NIS), however the selling prices will be linked to the Company’s price list which will be determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and its subsidiary operates. Thus, the dollar is the Company’s and its subsidiary functional and reporting currency.

Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the statements of operations as appropriate.

The functional currency of the affiliate company is the NIS and therefore foreign exchange differences are charged to the other comprehensive profit and loss.

Cash and cash equivalents
  c. Cash and cash equivalents:

Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.

Investment in affiliated companies
  d. Investment in affiliated companies

Affiliated company is company held to the extent of 20% or more (which are not subsidiary), or company less than 20% held, which the Company can exercise significant influence over operating and financial policy of the affiliate.

 

The investment in the affiliated company is accounted for by the equity method under ASC Subtopic 323-30, “Investments - Equity Method and Joint Ventures: Partnerships, Joint Ventures, and Limited Liability Entities”. Upon initial recognition, the cost of investment is based on the direct costs of acquiring the investment including amounts incurred on behalf of the investee.

Following the acquisition, the Company recognizes its proportionate share of the affiliated company’s net income or loss after the date of investment. When previous losses have reduced the Common Stock investment account to zero, the Company continues to report its share of equity method losses in its statement of operations to the extent of and as an adjustment to other investments in the investee such as debt securities, long term loans or advances, if any. Such additional equity method losses are applied to the other investments based on the seniority of the other investments (priority in liquidation) and the percentage ownership interest in each type of other investment the Company holds (the ‘relative holdings approach’).

Impairment of long-lived assets
  e. Impairment of long-lived assets:

The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the year ended December 31, 2023, no impairment losses were recorded.

Concentration of credit risks
  f. Concentration of credit risks:

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings.

The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.

Research and development expenses
  g. Research and development expenses:

Research and development costs are charged to the statement of operations as incurred.

Fair value of financial instruments
  h. Fair value of financial instruments:

ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

  Level 1 Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.
       
  Level 2 Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
       
  Level 3 Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The carrying amounts of cash and cash equivalents, other current assets, accounts payables and current liabilities approximate their fair value due to the short-term maturity of such instruments.

Income Tax
  i. Income Tax:

The Company account for income taxes in accordance with ASC 740, “Income Taxes” which prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will be realized. Based on ASC 740, a two-step approach is used to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.

The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2023, no liability for unrecognized tax positions has been recorded. Accordingly, no interest or penalties related to uncertain tax positions are recorded, either. It is the Company’s policy that any interest or penalties associated with unrecognized tax positions would be reflected in income tax expense.

Contingencies
  j. Contingencies:

The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

Stock-based payments
  k. Stock-based payments:

The Company measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.

Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, “Equity-Based Payments to Non-Employees”.

For the nine months ended September 30, 2024, the Company recorded $4, in share-based compensation (see note 5(b)).

v3.24.3
Investment in Affiliated Company (Tables)
9 Months Ended
Sep. 30, 2024
Investment in Affiliated Company [Abstract]  
Schedule of Equity Method Accounting for the Investment Affiliated The following table summarizes the equity method accounting for the investment in affiliated company:
Balance January 1, 2023  $152 
Share in losses of affiliated company   (27)
Foreign currency translation   (15)
Balance December 31, 2023  $110 
Share in losses of affiliated company   (30)
Foreign currency translation   (2)
Balance September 30, 2024  $78 
v3.24.3
Related Parties (Tables)
9 Months Ended
Sep. 30, 2024
Related Parties [Abstract]  
Schedule of Compensation to Key Management Personnel for Employment Services The compensation to key management personnel for employment services they provide to the Company is as follows:
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2024   2023   2024   2023 
Consulting Fees – CEO  $20   $21   $60   $63 
Consulting Fees - CFO  $9   $12   $27   $32 
Directors’ compensation  $21   $21   $63   $42 
Balances owed to (by) related parties
   September 30,   December 31, 
   2024   2023 
Consulting Fees – CEO  $20   $8 
Consulting Fees – CFO   12    8 
Directors   70    27 
Revoltz (see note 4b)   (64)   (62)
Xylo (see note 5c)   57    55 
   $95   $36 
v3.24.3
Common Stock and Preferred Stock (Tables)
9 Months Ended
Sep. 30, 2024
Common Stock and Preferred Stock [Abstract]  
Schedule of Share Capital As of September 30, 2024, and December 31, 2023, the Company’s share capital is composed as follows:
   September 30, 2024   December 31, 2023 
   Authorized   Issued and
outstanding
   Authorized   Issued and
outstanding
 
Shares of Common Stock   2,990,000,000    9,152,228    2,990,000,000    9,152,228 
Shares of Preferred Stock   10,000,000    
-
    10,000,000    
-
 
Schedule of Summary of Warrant Activity A summary of warrant activity during the period is as follows:
   Number   Average
weighted
exercise price
 
         
Warrants outstanding at December 31, 2023   6,150,000   $0.00 
Warrant Granted (iv)   122,831    12.82 
Warrants outstanding at September 30, 2024   6,272,831   $0.25 
           
Warrants exercisable at September 30, 2024   122,831   $12.82 
Schedule of Stock Options Activity On February 1, 2022, CR Israel issued 4 options to Ben Gurion University (the “BGU Options”) with an exercise price of $0.01. The BGU Options expire on January 1, 2032. The fair value of the BGU Options granted was $30, using the Black-Scholes option pricing model using the following assumptions:
    January
2022
 
CR Israel share price   $ 7,410  
CR Israel Exercise price   $ 0.01  
Dividend yield     0 %
Risk-free interest rate     0.48 %
Expected term (in years)     10  
Volatility     75 %
v3.24.3
General (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Feb. 14, 2024
Nov. 22, 2023
Apr. 06, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Apr. 07, 2023
Mar. 22, 2022
General [Line Items]                
Date of Incorporation       Mar. 25, 2008        
Par value (in Dollars per share)       $ 0.0001   $ 0.0001    
Total proceeds of private placement     $ 500 $ 500      
Total budget project   $ 445            
Finance percentage   50.00%            
Charging Robotics [Member]                
General [Line Items]                
Acquired interest percentage             100.00%  
Israel [Member]                
General [Line Items]                
Received           $ 77    
Additional received $ 33              
Common Stock [Member]                
General [Line Items]                
New issued share (in Shares)         910,000      
Par value (in Dollars per share)     $ 0.0001         $ 0.0001
Private Placement [Member]                
General [Line Items]                
New issued share (in Shares)     910,000          
v3.24.3
Unaudited Interim Condensed Financial Statements (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Unaudited Interim Condensed Financial Statements [Abstract]      
Income tax benefits 50.00%    
Unrecognized tax benefits, liability    
Share-based compensation $ 4 $ 9  
v3.24.3
Going Concern (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Going Concern [Abstract]    
Accumulated deficit $ (2,546) $ (1,966)
v3.24.3
Investment in Affiliated Company (Details) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended
Apr. 24, 2021
Sep. 30, 2024
Dec. 31, 2023
Jul. 28, 2022
Investment in Affiliated Company [Line Items]        
Purchase percentage 19.99%      
Aggregate amount   $ 1,000    
Loan principal amount   64 $ 62  
Robotics [Member]        
Investment in Affiliated Company [Line Items]        
Investments $ 250      
Revoltz [Member]        
Investment in Affiliated Company [Line Items]        
Investments       $ 60
Principal amount       $ 340
Aggregate amount   7,000    
Revenue   $ 1,000    
v3.24.3
Investment in Affiliated Company (Details) - Schedule of Equity Method Accounting for the Investment Affiliated - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Schedule of Equity Method Accounting for the Investment Affiliated [Abstract]    
Balance beginning $ 110 $ 152
Share in losses of affiliated company (30) (27)
Foreign currency translation (2) (15)
Balance ending $ 78 $ 110
v3.24.3
Related Parties (Details)
₪ in Thousands, $ in Thousands
12 Months Ended
Apr. 04, 2023
USD ($)
shares
Oct. 01, 2021
USD ($)
Dec. 31, 2022
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jan. 01, 2023
USD ($)
Oct. 01, 2021
ILS (₪)
Related Parties [Line Items]              
Loan balance $ 553            
Converted shares (in Shares) | shares 28            
Monthly fee   $ 7         ₪ 24,700
Stock options percentage   3.00%          
Valuation amount   $ 10,000          
Chief Executive Officer [Member]              
Related Parties [Line Items]              
Professional Fees       $ 60 $ 63    
Xylo Loan [Member]              
Related Parties [Line Items]              
Loan amount           $ 550  
Bears interest     2.42%        
Loan balance $ 509            
v3.24.3
Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employment Services - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Consulting Fees – CEO [Member]          
Schedule of Related Parties [Line Items]          
Related Party     $ 20   $ 8
Consulting Fees – CFO [Member]          
Schedule of Related Parties [Line Items]          
Related Party     12   8
Directors [Member]          
Schedule of Related Parties [Line Items]          
Related Party     70   27
Revoltz [Member]          
Schedule of Related Parties [Line Items]          
Related Party     (64)   (62)
Xylo [Member]          
Schedule of Related Parties [Line Items]          
Related Party     57   55
Related Party [Member]          
Schedule of Related Parties [Line Items]          
Related Party     95   $ 36
Key Management [Member] | Consulting Fees – CEO [Member]          
Schedule of Related Parties [Line Items]          
Related Party $ 20 $ 21 60 $ 63  
Key Management [Member] | Consulting Fees – CFO [Member]          
Schedule of Related Parties [Line Items]          
Related Party 9 12 27 32  
Key Management [Member] | Directors’ Compensation [Member]          
Schedule of Related Parties [Line Items]          
Related Party $ 21 $ 21 $ 63 $ 42  
v3.24.3
Common Stock and Preferred Stock (Details)
$ / shares in Units, $ in Thousands
2 Months Ended 9 Months Ended
Feb. 01, 2022
USD ($)
$ / shares
Jul. 31, 2024
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
shares
Jun. 20, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
Apr. 06, 2023
$ / shares
Mar. 22, 2022
$ / shares
shares
Common Stock and Preferred Stock [Line Items]                
Common stock shares authorized     2,990,000,000     2,990,000,000    
Common stock par value (in Dollars per share) | $ / shares     $ 0.0001     $ 0.0001    
Preferred stock shares authorized     10,000,000     10,000,000    
Preferred stock outstanding     0     0    
Preferred stock par value (in Dollars per share) | $ / shares     $ 0.0001     $ 0.0001    
Issued shares value (in Dollars) | $       $ 501        
Price per share (in Dollars per share) | $ / shares   $ 0.55            
Share-based compensation expense (in Dollars) | $       9        
Articles of Incorporation [Member]                
Common Stock and Preferred Stock [Line Items]                
Common stock shares authorized               2,990,000,000
Investor [Member]                
Common Stock and Preferred Stock [Line Items]                
Issued shares value (in Dollars) | $   $ 85            
Newly issued shares   154,545            
Warrants     6,150,000          
Acquisition Agreement [Member]                
Common Stock and Preferred Stock [Line Items]                
Share-based compensation expense (in Dollars) | $     $ 4          
Automax Motors Ltd [Member]                
Common Stock and Preferred Stock [Line Items]                
Warrants         122,831      
Exercise price (in Dollars per share) | $ / shares         $ 12.82      
Warrants expiry date         Sep. 20, 2027      
Fair value of warrants granted (in Dollars) | $         $ 19      
BGU Options [Member]                
Common Stock and Preferred Stock [Line Items]                
Number of options issued 4              
Exercise price (in Dollars per share) | $ / shares $ 0.01              
Options expiry date Jan. 01, 2032              
Fair value option granted (in Dollars) | $ $ 30              
Common Stock [Member]                
Common Stock and Preferred Stock [Line Items]                
Common stock par value (in Dollars per share) | $ / shares             $ 0.0001 $ 0.0001
Issued shares value (in Dollars) | $              
Newly issued shares       910,000        
Common Stock [Member] | Articles of Incorporation [Member]                
Common Stock and Preferred Stock [Line Items]                
Common stock par value (in Dollars per share) | $ / shares               $ 0.0001
Common Stock [Member] | Share Capital [Member]                
Common Stock and Preferred Stock [Line Items]                
Common stock shares authorized               3,000,000,000
Preferred Stock [Member]                
Common Stock and Preferred Stock [Line Items]                
Preferred stock shares authorized               10,000,000
v3.24.3
Common Stock and Preferred Stock (Details) - Schedule of Share Capital - shares
Sep. 30, 2024
Dec. 31, 2023
Shares of Common Stock [Member]    
Schedule of Composed Share Capital [Line Items]    
Common shares, Authorized 2,990,000,000 2,990,000,000
Common shares, Issued 9,152,228 9,152,228
Common shares, Outstanding 9,152,228 9,152,228
Preferred Shares [Member]    
Schedule of Composed Share Capital [Line Items]    
Preferred shares, Authorized 10,000,000 10,000,000
Preferred shares, Issued
Preferred shares, Outstanding
v3.24.3
Common Stock and Preferred Stock (Details) - Schedule of Summary of Warrant Activity
9 Months Ended
Sep. 30, 2024
$ / shares
shares
Schedule of Summary of Warrant Activity [Abstract]  
Number, Warrants outstanding,Beginning balance | shares 6,150,000
Average weighted exercise price, Warrants outstanding, Beginning balance | $ / shares $ 0
Number, Warrant Granted | shares 122,831
Average weighted exercise price, Warrant Granted | $ / shares $ 12.82
Number, Warrants outstanding, Ending balance | shares 6,272,831
Average weighted exercise price, Ending balance | $ / shares $ 0.25
Number, Warrants exercisable | shares 122,831
Average weighted exercise price, Warrants exercisable | $ / shares $ 12.82
v3.24.3
Common Stock and Preferred Stock (Details) - Schedule of Stock Options Activity
1 Months Ended
Jan. 31, 2022
$ / shares
Schedule of Stock Options Activity [Abstract]  
CR Israel share price (in Dollars per share) $ 7,410
CR Israel Exercise price (in Dollars per share) $ 0.01
Dividend yield 0.00%
Risk-free interest rate 0.48%
Expected term (in years) 10 years
Volatility 75.00%

Charging Robotics (PK) (USOTC:CHEV)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Charging Robotics (PK) Charts.
Charging Robotics (PK) (USOTC:CHEV)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Charging Robotics (PK) Charts.